COPD患者使用β受体阻滞剂:TONADO研究项目队列分析
该事后分析基于TONADO 1和2两项III期研究(共5162例中重度至极重度COPD患者),评估基线使用β受体阻滞剂对长效支气管舒张剂治疗1年内肺功能、患者报告结局及安全性的影响。结果显示,557例(11%)基线使用β受体阻滞剂,其肺功能、SGRQ、TDI及安全性与未使用者无显著差异,支持在合并心血管疾病的COPD患者中谨慎使用β受体阻滞剂。
要点
- 基线使用β受体阻滞剂未影响COPD患者肺功能改善。
- β受体阻滞剂组与未使用组患者报告结局无显著差异。
- 两组安全性相当,支持谨慎使用β受体阻滞剂。
核心结论
- 在合并心血管疾病的COPD患者中,基线使用β受体阻滞剂未影响噻托溴铵/奥达特罗的肺功能、整体呼吸状态及安全性。
研究设计与样本
- TONADO 1和2两项III期研究的事后分析,共纳入5162例中重度至极重度COPD患者,接受长效支气管舒张剂治疗1年。
主要发现
- 557/5162例(11%)基线使用β受体阻滞剂,该组基线支气管舒张后FEV1为1.470 L,高于未使用组的1.362 L。
- β受体阻滞剂组心血管合并症及用药史更常见。
- 两组在第24周和第52周的谷值FEV1或谷值FVC无相关组间差异。
- 两组SGRQ和TDI结果无相关差异,安全性发现相当。
临床怎么用
- 对于合并心血管疾病的COPD患者,可谨慎且适当地使用β受体阻滞剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in preventing cardiovascular events. METHODS: The large (5,162 patients) phase III TONADO 1 and 2 studies assessed lung function and patient-reported outcomes in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment across 1 year. This post hoc analysis characterized lung-function changes, patient-reported outcomes, and safety in the subgroup of patients receiving β-blockers in the studies. RESULTS: In total, 557 of 5,162 patients (11%) received β-blockers at baseline. Postbronchodilator FEV1 at baseline was higher in the β-blocker group (1.470 L) compared with that in the no β-blocker group (1.362 L). As expected, patients receiving β-blockers had a more frequent history of cardiovascular comorbidities and medications. Lung function improved from baseline in patients with or those without β-blocker treatment, and no relevant between-group differences were observed in trough FEV1 or trough FVC at 24 or 52 weeks. No relevant differences were observed for St. George's Respiratory Questionnaire results and Transition Dyspnea Index in patients with β-blockers compared with those in patients without. Safety findings were comparable between groups. CONCLUSIONS: Lung function, overall respiratory status, and safety of tiotropium/olodaterol were not influenced by baseline β-blocker treatment in patients with moderate to very severe COPD. Results from this large patient cohort support the cautious and appropriate use of β-blockers in patients with COPD and cardiovascular comorbidity. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01431274 and No. NCT01431287; URL: www.clinicaltrials.gov.
引用
- Maltais F, Buhl R, Koch A, et al. β-Blockers in COPD: A Cohort Study From the TONADO Research Program. Chest. 2018. PMID: 29355547. doi:10.1016/j.chest.2018.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。